The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant… The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…

The FDA Is Trying To Make Corporate Free Speech Situational

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images)

Getty Images

While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future.

Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit.

The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music.

Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant to create a healthier future, they made sure to downplay or outright deny their achievements?

Makary pats his FDA and Trump administration on the back for acting to “rein in misleading pharmaceutical ads,” but it’s the equivalent of the Trump administration demanding that pharmaceutical companies demean their capabilities. How could the allegedly pro-business Trump administration make such a demand, one that no other politician or business would ever be expected to abide?

To which Makary and his defenders might reply that with pharmaceutical drugs, the rules should be different. Since health and health outcomes are on the line, sometimes of the life and death variety, pharmaceutical companies must follow a different set of rules. Except that pharmaceutical companies already do. And Makary knows this truth well.

As evidenced by the years of work and billions spent just to attain drug approval, pharmaceutical companies go to enormous lengths to get their innovations into the marketplace. Their drugs are FDA approved. Which is the point, or should be.

In seeking greater policing of drug advertising, Makary is adding another layer to the already substantial oversight provided by the FDA, oversight that has yet more layers. While pharmaceutical companies can advertise their FDA approved drugs, would-be patients can still only attain them insofar as they’re prescribed by a doctor. Which of course answers Makary’s odd critique that drugmakers are targeting potential users with “misleading ads.” Really? How?

Lest Makary forget, the ads are yet again for FDA approved drugs that are once again only accessible with a doctor-signed prescription. Which raises a basic question: if the FDA is doing its job in the approval process, and doctors are doing their jobs, why the limits on the free speech rights of pharmaceutical companies to advertise the health possibilities that come with their innovations? Why indeed.

Absent a compelling answer from Makary, it’s difficult to find a compelling reason for the Trump administration to make free speech situational. Pharmaceutical companies prosper by improving our lives. Let them advertise their capacity to do just that.

Source: https://www.forbes.com/sites/johntamny/2025/09/17/the-fda-is-trying-to-make-corporate-free-speech-situational/

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.005726
$0.005726$0.005726
+3.24%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Sobering warning issued about America's 'ticking time-bombs' Trump may soon detonate

Sobering warning issued about America's 'ticking time-bombs' Trump may soon detonate

An economics expert issued a sobering warning on Thursday about the impact President Donald Trump's war in Iran could have at home. Catherine Rampell, economics
Share
Rawstory2026/03/20 09:03
Trump tells Israel not to repeat strikes on Iranian energy as crisis deepens

Trump tells Israel not to repeat strikes on Iranian energy as crisis deepens

QatarEnergy's liquefied natural gas production facilities, amid the US-Israeli conflict with Iran, in Ras Laffan Industrial City, Qatar March 2, 2026.
Share
Rappler2026/03/20 09:08
BlockDAG’s $0.0013 Entry Draws Market Attention Ahead of Deadline

BlockDAG’s $0.0013 Entry Draws Market Attention Ahead of Deadline

The post BlockDAG’s $0.0013 Entry Draws Market Attention Ahead of Deadline appeared on BitcoinEthereumNews.com. Crypto News 20 September 2025 | 00:00 Discover why BlockDAG’s $0.0013 entry is making headlines with nearly $410M raised, 26.3B coins sold, and the limited-time entry closing on Oct 1st. Occasionally, a single figure captures attention across crypto. This time, it isn’t a projection or a chart setup; it is a presale entry point. The $0.0013 price lock from BlockDAG (BDAG) has become more than a presale detail. It represents a marker of timing, reliability, and measurable progress. With more than 26.3 billion coins sold and nearly $410 million already secured, this price is not a teaser. It is a structured offer that continues to attract participants in large numbers. Once October 1st passes, the $0.0013 entry will close, and its significance could be remembered as one of those rare early-stage milestones. The $0.0013 Window Reflects More Than a Temporary Offer Many presales are defined by uncertainty, often shifting timelines and unclear goals. By fixing its presale price at $0.0013 until October 1st, BlockDAG has created a point of clarity in a crowded market. It is less about a discount and more about a defined statement: the project is setting a clear cut-off for early access. This approach has shown results. Over 26.3 billion BDAG coins have already been purchased. That momentum stems from demonstrated progress, not just speculation. A live Testnet, close to 20,000 miners distributed, and more than 3 million daily users of the X1 mobile miner all point to activity happening now rather than deferred promises. On top of this, the return profile is notable. The current batch price is $0.03, while the $0.0013 entry remains open for a limited time. That gap means an ROI of about 2,900% compared with batch 1. Even so, the project is keeping the entry level steady until October 1st, providing…
Share
BitcoinEthereumNews2025/09/20 06:25